NO318818B1 - Farmasoytisk preparat som omfatter modafinil som har definert partikkelstorrelse, fremgangsmater for fremstilling derav, samt anvendelser av modafinil for fremstilling av en farmasoytisk blanding - Google Patents
Farmasoytisk preparat som omfatter modafinil som har definert partikkelstorrelse, fremgangsmater for fremstilling derav, samt anvendelser av modafinil for fremstilling av en farmasoytisk blanding Download PDFInfo
- Publication number
- NO318818B1 NO318818B1 NO19971541A NO971541A NO318818B1 NO 318818 B1 NO318818 B1 NO 318818B1 NO 19971541 A NO19971541 A NO 19971541A NO 971541 A NO971541 A NO 971541A NO 318818 B1 NO318818 B1 NO 318818B1
- Authority
- NO
- Norway
- Prior art keywords
- particles
- modafinil
- diameter
- median
- range
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 185
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 184
- 229960001165 modafinil Drugs 0.000 title claims abstract description 180
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 230000001186 cumulative effect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 206010041349 Somnolence Diseases 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 208000032140 Sleepiness Diseases 0.000 claims description 10
- 201000003631 narcolepsy Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000008240 homogeneous mixture Substances 0.000 claims description 5
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 claims description 4
- 229940119743 dextran 70 Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000006194 liquid suspension Substances 0.000 claims 3
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 238000005259 measurement Methods 0.000 description 13
- 239000003937 drug carrier Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000399 optical microscopy Methods 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012538 light obscuration Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical class C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- 208000001573 Cataplexy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028714 Narcolepsy and hypersomnia Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 acetamide compound Chemical class 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005323 electroforming Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000008430 psychophysiology Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Developing Agents For Electrophotography (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Paints Or Removers (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Slot Machines And Peripheral Devices (AREA)
- Packaging For Recording Disks (AREA)
- Laminated Bodies (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/319,124 US5618845A (en) | 1994-10-06 | 1994-10-06 | Acetamide derivative having defined particle size |
| PCT/US1995/012944 WO1996011001A1 (en) | 1994-10-06 | 1995-10-04 | Modafinil having defined particle size |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971541D0 NO971541D0 (no) | 1997-04-04 |
| NO971541L NO971541L (no) | 1997-06-04 |
| NO318818B1 true NO318818B1 (no) | 2005-05-09 |
Family
ID=23240954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971541A NO318818B1 (no) | 1994-10-06 | 1997-04-04 | Farmasoytisk preparat som omfatter modafinil som har definert partikkelstorrelse, fremgangsmater for fremstilling derav, samt anvendelser av modafinil for fremstilling av en farmasoytisk blanding |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US5618845A (ru) |
| EP (3) | EP0731698B1 (ru) |
| JP (1) | JP2915146B2 (ru) |
| KR (1) | KR100249360B1 (ru) |
| AT (3) | ATE400260T1 (ru) |
| AU (1) | AU703087B2 (ru) |
| BG (1) | BG62952B1 (ru) |
| BR (1) | BR9509257A (ru) |
| CA (2) | CA2201967C (ru) |
| CZ (1) | CZ291700B6 (ru) |
| DE (3) | DE69520161T2 (ru) |
| DK (3) | DK1088549T3 (ru) |
| EE (1) | EE9700082A (ru) |
| ES (3) | ES2142499T3 (ru) |
| FI (1) | FI121454B (ru) |
| GB (1) | GB2293103B (ru) |
| GR (2) | GR3033152T3 (ru) |
| HK (3) | HK1003561A1 (ru) |
| HU (1) | HU226411B1 (ru) |
| IS (1) | IS1987B (ru) |
| LT (1) | LT4303B (ru) |
| LV (1) | LV11852B (ru) |
| MD (1) | MD970143A (ru) |
| MX (1) | MX9602176A (ru) |
| NO (1) | NO318818B1 (ru) |
| NZ (1) | NZ295869A (ru) |
| PL (1) | PL181523B1 (ru) |
| PT (3) | PT966962E (ru) |
| RO (1) | RO118928B1 (ru) |
| RU (1) | RU2287987C2 (ru) |
| SI (1) | SI9520106B (ru) |
| SK (1) | SK283632B6 (ru) |
| UA (1) | UA42023C2 (ru) |
| WO (1) | WO1996011001A1 (ru) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| UA71629C2 (en) * | 1999-08-03 | 2004-12-15 | Lilli Icos Llc | Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
| US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| EP1309547B1 (en) * | 2000-07-27 | 2007-01-17 | Teva Pharmaceutical Industries Ltd. | Crystalline and pure modafinil, and process of preparing the same |
| WO2002030414A1 (en) * | 2000-10-11 | 2002-04-18 | Cephalon, Inc. | Compositions comprising modafinil compounds |
| US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| PL215226B1 (pl) * | 2000-10-11 | 2013-11-29 | Cephalon | Kompozycja farmaceutyczna zawierajaca zwiazek modafinilu, sposób jej wytwarzania oraz jej zastosowanie |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7576133B2 (en) | 2002-03-11 | 2009-08-18 | Carl Henry Lawyer | Methods and compositions for nasal administration of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| MY137846A (en) | 2002-07-08 | 2009-03-31 | Ranbaxy Lab Ltd | Processes for the preparation of oral dosage formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| AU2003247001A1 (en) * | 2002-07-25 | 2004-02-16 | Ranbaxy Laboratories Limited | Processes for the preparation of oral dosage formulations of modafinil |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20040138180A1 (en) * | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| CA2420180A1 (en) * | 2003-02-28 | 2004-08-28 | Bernard Charles Sherman | Tablets comprising modafinil |
| US20070066996A1 (en) * | 2003-03-17 | 2007-03-22 | Katzman Daniel E | Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| ES2330321T3 (es) * | 2003-05-16 | 2009-12-09 | Cephalon France | Procedimiento de sintesis de modafinilo. |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US20050137264A1 (en) * | 2003-12-22 | 2005-06-23 | Patel Ashish A. | Modafinil compositions |
| EP2292213A1 (en) | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| CA2614777C (en) * | 2005-07-21 | 2012-04-17 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| EP1951197A4 (en) * | 2005-11-10 | 2011-12-21 | Alphapharm Pty Ltd | METHOD OF CHECKING THE PARTICLE SIZE |
| EP2043623A4 (en) * | 2006-07-12 | 2013-03-20 | Elan Pharma Int Ltd | NANOPARTICLE FORMULATIONS OF MODAFINIL |
| US7884135B2 (en) * | 2006-08-14 | 2011-02-08 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| EP2476418A1 (en) | 2006-12-21 | 2012-07-18 | Alphapharm Pty Ltd. | Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| US20110206770A1 (en) * | 2008-07-25 | 2011-08-25 | Alphapharm Pty. Ltd. | Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns |
| US20100036164A1 (en) * | 2008-08-06 | 2010-02-11 | Srinivas Areveli | Preparation of armodafinil form i |
| EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| FR2987266B1 (fr) * | 2012-02-28 | 2014-12-19 | Debregeas Et Associes Pharma | Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application |
| FR2987267B1 (fr) * | 2012-02-28 | 2015-01-16 | Debregeas Et Associes Pharma | Application du modafinil dans le traitement de substitution des cacainomanes |
| FR2987265B1 (fr) * | 2012-02-28 | 2014-02-28 | Debregeas Et Associes Pharma | Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002718A (en) * | 1974-10-16 | 1977-01-11 | Arnar-Stone Laboratories, Inc. | Gelatin-encapsulated digoxin solutions and method of preparing the same |
| FR2408345A1 (fr) * | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
| US4122157A (en) * | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| IT1130924B (it) * | 1980-03-06 | 1986-06-18 | Secifarma Spa | Procedimento per la preparazione di spironolattone micronizzato |
| US4600614A (en) * | 1983-09-12 | 1986-07-15 | The Dow Chemical Company | High-frequency heatable plastics |
| US4713246A (en) * | 1984-03-19 | 1987-12-15 | Bristol-Myers Company | Etoposide oral dosage form |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| DE3720493A1 (de) * | 1987-06-20 | 1989-01-26 | Nattermann A & Cie | Arzneizubereitungen mit mikronisierten ebselen-kristallen |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2702968B1 (fr) * | 1993-03-23 | 1995-06-23 | Lafon Labor | Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation . |
| JP3795519B2 (ja) | 1993-04-05 | 2006-07-12 | エスディーエス プロプライアタリー リミテッド | 衝撃式穿孔の改良 |
| FR2706767B1 (ru) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2708201B1 (fr) * | 1993-06-30 | 1995-10-20 | Lafon Labor | Utilisation de dérivés d'acétamide pour la fabrication de médicaments. |
| US5493146A (en) | 1994-07-14 | 1996-02-20 | Vlsi Technology, Inc. | Anti-fuse structure for reducing contamination of the anti-fuse material |
-
1994
- 1994-10-06 US US08/319,124 patent/US5618845A/en not_active Ceased
-
1995
- 1995-10-04 CA CA002201967A patent/CA2201967C/en not_active Expired - Lifetime
- 1995-10-04 UA UA97041604A patent/UA42023C2/ru unknown
- 1995-10-04 EE EE9700082A patent/EE9700082A/xx unknown
- 1995-10-04 EP EP95937389A patent/EP0731698B1/en not_active Expired - Lifetime
- 1995-10-04 CA CA002382275A patent/CA2382275C/en not_active Expired - Lifetime
- 1995-10-04 DK DK00125091T patent/DK1088549T3/da active
- 1995-10-04 RO RO97-00664A patent/RO118928B1/ro unknown
- 1995-10-04 HU HU9800737A patent/HU226411B1/hu unknown
- 1995-10-04 PT PT99202603T patent/PT966962E/pt unknown
- 1995-10-04 DE DE69520161T patent/DE69520161T2/de not_active Expired - Lifetime
- 1995-10-04 GB GB9524328A patent/GB2293103B/en not_active Revoked
- 1995-10-04 EP EP00125091A patent/EP1088549B1/en not_active Expired - Lifetime
- 1995-10-04 PL PL95319480A patent/PL181523B1/pl unknown
- 1995-10-04 ES ES95937389T patent/ES2142499T3/es not_active Expired - Lifetime
- 1995-10-04 SI SI9520106A patent/SI9520106B/sl unknown
- 1995-10-04 MD MD97-0143A patent/MD970143A/ru unknown
- 1995-10-04 NZ NZ295869A patent/NZ295869A/en not_active IP Right Cessation
- 1995-10-04 SK SK445-97A patent/SK283632B6/sk not_active IP Right Cessation
- 1995-10-04 WO PCT/US1995/012944 patent/WO1996011001A1/en active IP Right Grant
- 1995-10-04 EP EP99202603A patent/EP0966962B1/en not_active Expired - Lifetime
- 1995-10-04 AT AT00125091T patent/ATE400260T1/de active
- 1995-10-04 DK DK200001006T patent/DK0966962T3/da active
- 1995-10-04 AT AT95937389T patent/ATE188607T1/de active
- 1995-10-04 BR BR9509257A patent/BR9509257A/pt not_active IP Right Cessation
- 1995-10-04 MX MX9602176A patent/MX9602176A/es unknown
- 1995-10-04 JP JP8512675A patent/JP2915146B2/ja not_active Expired - Lifetime
- 1995-10-04 PT PT95937389T patent/PT731698E/pt unknown
- 1995-10-04 DE DE69514497T patent/DE69514497T2/de not_active Expired - Lifetime
- 1995-10-04 ES ES00125091T patent/ES2308960T3/es not_active Expired - Lifetime
- 1995-10-04 CZ CZ19971032A patent/CZ291700B6/cs not_active IP Right Cessation
- 1995-10-04 PT PT00125091T patent/PT1088549E/pt unknown
- 1995-10-04 ES ES99202603T patent/ES2156457T3/es not_active Expired - Lifetime
- 1995-10-04 DE DE69535786T patent/DE69535786D1/de not_active Expired - Lifetime
- 1995-10-04 DK DK95937389T patent/DK0731698T3/da active
- 1995-10-04 AU AU39514/95A patent/AU703087B2/en not_active Expired
- 1995-10-04 AT AT99202603T patent/ATE199216T1/de active
- 1995-10-04 KR KR1019970702247A patent/KR100249360B1/ko not_active IP Right Cessation
-
1997
- 1997-03-24 IS IS4451A patent/IS1987B/is unknown
- 1997-04-03 LT LT97-060A patent/LT4303B/lt not_active IP Right Cessation
- 1997-04-04 LV LVP-97-55A patent/LV11852B/xx unknown
- 1997-04-04 NO NO19971541A patent/NO318818B1/no not_active IP Right Cessation
- 1997-04-04 BG BG101389A patent/BG62952B1/bg unknown
- 1997-04-04 FI FI971417A patent/FI121454B/fi not_active IP Right Cessation
-
1998
- 1998-03-27 HK HK98102611A patent/HK1003561A1/xx not_active IP Right Cessation
-
1999
- 1999-04-01 US US09/285,166 patent/USRE37516E1/en not_active Expired - Lifetime
-
2000
- 2000-04-04 GR GR20000400845T patent/GR3033152T3/el unknown
- 2000-06-19 HK HK00103669A patent/HK1024625A1/xx not_active IP Right Cessation
-
2001
- 2001-02-22 GR GR20010400165T patent/GR3035451T3/el unknown
- 2001-05-17 RU RU2001113686/15A patent/RU2287987C2/ru active
- 2001-08-01 HK HK01105376A patent/HK1034676A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO318818B1 (no) | Farmasoytisk preparat som omfatter modafinil som har definert partikkelstorrelse, fremgangsmater for fremstilling derav, samt anvendelser av modafinil for fremstilling av en farmasoytisk blanding | |
| KR20190130625A (ko) | 니라파립 제제 | |
| NO334450B1 (no) | Farmasøytiske sammensetninger av modafinil, fremgangsmåter for formulering derav, farmasøytisk doseringsenhet samt anvendelse | |
| BR112015025058B1 (pt) | Composição farmacêutica do tipo matriz contendo lacosamida | |
| Odaci et al. | Effects of low‐dose oxcarbazepine administration on developing cerebellum in newborn rat: A stereological study | |
| AU729586B2 (en) | Modafinil having defined particle size | |
| Limpa et al. | Comparative Evaluation of Bromhexine HCl Mucoadhesive Microspheres Prepared by Anionic, Cationic and Nonionic Polymers | |
| RU2171674C2 (ru) | Модафинил с определенным размером частиц | |
| Dhat et al. | Effect of two different diluents on release profile of aceclofenac from sustained release matrix tablets using gum damar as release retardant | |
| Jaiswal et al. | Formulation, Evaluation and Optimization of Solid Dispersion Tablet of Combination of Repaglinide and Metformin Hydrochloride Using Face Centered Central Composite Design | |
| Amaresh et al. | The Plackett-Burman model-An Improved Alternative to Identify the Significant Factors Implied in the Preparation of Tramadol Hydrochloride Microsphere | |
| Kutmalge et al. | Formulation and in-vitro evaluation of lornoxicam floating microsphere | |
| Hiremath | Formulation and Evaluation of Microcapsules for Controlled Release of Anti Diabetic Drug by Ionotropic Gelation Technique | |
| shukla VermaPrincipal et al. | FORMULATION DESIGN, DEVELOPMENT AND EVALUATION OF FLOATING MICROSPHERE | |
| Ababa et al. | In vitro quality evaluation of metformin hydrochloride tablets marketed in |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LIS | Published licence |
Effective date: 20100506 |
|
| MK1K | Patent expired |